2 recruiting, 1 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Recruiting 2, Completed 1 |
Follow Janssen Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis Ustekinumab 90 mg SC q8w, Ustekinumab 90 mg SC q12w - Crohn Disease (CD), Ulcerative Colitis (UC) | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 115 | 2025-10-08 | 2025-12-26 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy Infliximab 5 mg/kg body weight infused over 2 hours - Crohn's Disease | Phase 4 | Completed | Janssen Inc. | 1 | 2012-06-01 | 2013-12-16 |
Crohn Disease (2) · Colitis, Ulcerative (1) · Multiple Myeloma (1) · Neoplasms (1) · Recurrence (1)
Infliximab (1) · Ustekinumab (1) · tocilizumab (1)
Canada (3)